

# Matthew W Sherwood

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4457182/matthew-w-sherwood-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70 papers	4,087 citations	25 h-index	63 g-index
91 ext. papers	5,368 ext. citations	6.9 avg, IF	5.31 L-index

#	Paper	IF	Citations
70	Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes.. <i>Circulation: Heart Failure</i> , <b>2022</b> , 101161CIRCHEARTFAILURE121009279 <sup>1</sup>	7.6	279 <sup>1</sup>
69	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , <b>2021</b> , 44, 1219-1227	14.6	9
68	Ventricular septal rupture and cardiogenic shock complicating STEMI during COVID-19 pandemic: An old foe re-emerges. <i>Heart and Lung: Journal of Acute and Critical Care</i> , <b>2021</b> , 50, 292-295	2.6	6
67	Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e009963	6	1
66	Transradial access in acute myocardial infarction complicated by cardiogenic shock: Stratified analysis by shock severity. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, 1354-1366	2.7	3
65	Myocarditis Temporally Associated With COVID-19 Vaccination. <i>Circulation</i> , <b>2021</b> , 144, 502-505	16.7	88
64	The clinical spectrum of myocardial injury associated with COVID-19 infection. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2020</b> , 10, 521-522	1.1	1
63	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008274	6	1
62	Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC/SCAI Interventional Council and SCAI. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2372-2375 <sup>15,1</sup>	15.1	277
61	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 484-498	5.1	3
60	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Society. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008274	6	11
59	Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: An ACC/SCAI position statement. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, 659-663	2.7	23
58	Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic: An ACC/SCAI Position Statement. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1484-1488 <sup>52</sup>	5	1488 <sup>52</sup>
57	Transcatheter Aortic Valve Replacement in Low-Population Density Areas: Assessing Healthcare Access for Older Adults With Severe Aortic Stenosis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006245	5.8	4
56	Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement. <i>American Heart Journal</i> , <b>2020</b> , 224, 171-181	4.9	8
55	Incidence, Prognosis and Predictors of Major Vascular Complications and Percutaneous Closure Device Failure Following Contemporary Percutaneous Transfemoral Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 1065-1073	1.6	7
54	Radial Artery Remodeling following Transradial Percutaneous Coronary Intervention in Men and Women: Insights from Serial Ultrahigh Frequency Ultrasonography. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 286-292	1.6	4

53	Incidence and Outcomes of Surgical Bypass During TAVR: Insights From the STS/ACC TVT Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1751-1764	5	15
52	Standardized Team-Based Care for Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1659-1669	15.1	163
51	Relation of Postdischarge Care Fragmentation and Outcomes in Transcatheter Aortic Valve Implantation from the STS/ACC TVT Registry. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 912-919	3	3
50	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 618-628	18.1	120
49	Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1233-1242	3.7	7
48	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , <b>2019</b> , 139, 458-472	16.7	20
47	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 387-396	15.1	96
46	The risk-adjusted return potential of integrating ESG strategies into emerging market equities. <i>Journal of Sustainable Finance and Investment</i> , <b>2018</b> , 8, 26-44	3	20
45	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , <b>2018</b> , 197, 1-8	4.9	5
44	Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. <i>American Heart Journal</i> , <b>2018</b> , 204, 9-16	4.9	25
43	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , <b>2018</b> , 197, 133-141	4.9	16
42	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2097-2107	59.2	1277
41	Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 130	4.2	4
40	Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1746-1756	5	50
39	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , <b>2018</b> , 138, 1402-1411	16.7	14
38	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	23
37	Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2913-2924	15.1	60
36	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention: A Report From the NCDR. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 672-682	5	13

35	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	10
34	Challenges in Aortic Valve Stenosis: Low-Flow States Diagnosis, Management, and a Review of the Current Literature. <i>Current Cardiology Reports</i> , <b>2017</b> , 19, 130	4.2	3
33	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	45
32	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1694-702	5	19
31	To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 2556-2559	15.4	23
30	Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 578-584	3.3	2
29	Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 875-85	15.4	99
28	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	76
27	Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. <i>Circulation</i> , <b>2016</b> , 134, 365-74	16.7	63
26	Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4,	6	52
25	TCT-103 National variation in post-TAVR antithrombotic therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry . <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, B47-B48	15.1	6
24	Risk Adjusted Mortality Ratings and Public Reporting for High-Risk PCI. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1134-1135	5	2
23	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2271-2281	15.1	127
22	Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes: a systematic review and meta-analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 436-446	5	44
21	Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1868-76	5	12
20	The impact of extreme-risk cases on hospitalsTrisk-adjusted percutaneous coronary intervention mortality ratings. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 10-6	5	22
19	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , <b>2015</b> , 169, 315-22	4.9	8
18	Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Circulation</i> , <b>2015</b> , 131, 488-94	16.7	179

17	Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodology. <i>American Heart Journal</i> , <b>2014</b> , 167, 15-21.e3	4.9	37
16	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 891-900	15.1	172
15	High-sensitivity troponin assays: evidence, indications, and reasonable use. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000403	6	85
14	Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000849	6	75
13	Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 836-43	27.4	57
12	The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 2016-22; discussion 2022	2.7	61
11	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). <i>Circulation</i> , <b>2014</b> , 129, 1850-9	16.7	188
10	Revascularization in stable coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2028-9	27.4	
9	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 163-74	5.1	15
8	Acute coronary syndromes: Blood transfusion in patients with acute MI and anaemia. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 186-7	14.8	9
7	For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding. <i>Evidence-Based Medicine</i> , <b>2012</b> , 17, 148-9		
6	How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2011</b> , 13, 46-56	2.1	1
5	Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLOpidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. <i>American Heart Journal</i> , <b>2010</b> , 159, 964-971.e1	4.9	11
4	Staphylococcus aureus endocarditis: The Grady Memorial Hospital Experience. <i>American Journal of the Medical Sciences</i> , <b>2006</b> , 331, 84-7	2.2	9
3	Continuous cardiac output monitoring with pulse contour analysis: a comparison with lithium indicator dilution cardiac output measurement. <i>Critical Care Medicine</i> , <b>2005</b> , 33, 2015-21	1.4	120
2	A comparison of HIV-positive patients with and without infective endocarditis: an echocardiographic study--the Emory Endocarditis Group experience. <i>American Journal of the Medical Sciences</i> , <b>2004</b> , 328, 145-9	2.2	8
1	Tracheoscopy with the rapscope to verify endotracheal tube placement. <i>Journal of Clinical Anesthesia</i> , <b>2003</b> , 15, 334-8	1.9	5